The benefits of mammography are not limited to women of ages older than 50 years

Cancer

Volumn 82, Issue 11, 1998, Pages 2221-2226

  Heimann, Ruth ^a   Bradley, Jeffrey ^a   Hellman, Samuel ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Age; Breast carcinoma; Mammography; Recurrence; Survival

Indexed keywords

ADULT; AGE; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; SURVIVAL RATE;

EID: 0032104283     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980601)82:11<2221::AID-CNCR17>3.0.CO;2-W     Document Type: Article

References (42)

1. Ries LA, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK. SEER cancer statistics review, 1973-1991: Tables and graphs. Bethesda (MD): National Cancer Institute; 1994 NIH Pub. No. 94-2789.
2. Carter CL, Allen C, Henson DE. Relationship of tumor staging lymph node staging status and survival in 24,470 breast cancer cases. Cancer 1989;63:181-7.
3. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997;47:28-51.
4. Hellman S. Karnofsky Memorial Lecture. Natural history of small breast cancers. J Clin Oncol 1994;12:2229-34.
5. Quiet CA, Ferguson DJ, Weichselbaum RR, Hellman S. Natural history of node-negative breast cancer: a study of 826 patients with long-term follow up. J Clin Oncol 1995;13: 1144-51.
6. Rosen PR, Groshen S, Saigo PE, Kinne DW, Hellman S. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7(3):355-66.
7. Smart CR, Byrne C, Smith RA, Garfinkel L, Letton AH, Dodd GD, et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1997;47:134-49.
8. Osteen R, Cady B, Chmiel JS, Clive RE, Doggett RLS, Friedman MA, et al. 1991 National survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg 1994; 178:213-9.
9. Chu KC, Smart CR, Tarone RE. Analysis of breast cancer mortality and stage distribution by age for the Health Insurance Plan clinical trial. J Natl Cancer Inst 1988;80:1125-32.
10. Shapiro S, Venet W, Strax P, Venet L. Ten to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982;69:349-55.
11. Smart RC, Hartmann WH, Beahrs OH, Garfinkel L. Insight into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Detection and Demonstration Project. Cancer 1993;72:1449-56.
12. Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 1993;341:973-8.
13. Andersson I, Aspergen K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988;297:943-8.
14. Roberts MM, Alexander FE, Anderson TJ, Chetty U, Donnan PT, Forest P, et al. Edinburg trial of screening for breast cancer: mortality at seven years. Lancet 1990;335:241-6.
15. Tabar L, Fagenberg CJ, Gad A, Baldertrop L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography: randomised trial from the breast cancer screening working group of the Swedish national board of health and welfare. Lancet 1985; 1:829-32.
16. Tabar L, Fagenberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992;30:37-59.
17. Frissell J, Eklund G, Hellstrom L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening-preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 1992;18:49-56.
18. Miller A, Baines CJ, To T, Wall C. Canadian national breast screening study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Can Med Assoc J 1992; 147:1459-76.
19. Miller A, Baines CJ, To T, Wall C. Canadian national breast screening study: 1. Breast cancer detection and death rates among women aged 50 to 59 years. Can Med Assoc J 1992; 147:1477-88.
20. Taubes G. The breast-screening brawl. Science 1997;275:1056-9.
21. Smart CR, Hendrick RE, Rutledge JH, Smith RA. Benefit of mammography screening in women ages 40 to 49 years. Current evidence from randomized controlled trials. Cancer 1995;75:1619-26.
22. Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the international workshop on screening for breast cancer. J Natl Cancer Inst 1993;85:1644-56.
23. NIH consensus conference on breast cancer screening in women ages 40-49. Monogr Natl Cancer Inst 1997;22:1-156.
24. Bjurstam N, Bjorneld L, Duffy SW, Smith T, Cahlin E, Erikson O, et al. The Gothenburg breast cancer screening trial. First results on mortality, incidence and mode of detection for women ages 39-49 years at randomization. Cancer 1997; 80:2091-9.
25. Kerlikowske K, Grady D, Barklay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33-8.
26. Peer PGM, van Dijck JAAM, Hendriks JHCL, Holland R, Verbeek ALM. Age dependent growth rate of primary breast cancer. Cancer 1993;71:3547-51.
27. Kopans DB, Halpern E, Hulka CA. Statistical power in breast cancer screening trials and mortality reduction among women 40-49 years of age with particular emphasis on the National Breast Screening Study of Canada. Cancer 1994;74:1196-203.
28. Feig SA. Determination of mammographic screening intervals with surrogate measures for women aged 40-49 years. Radiology 1994;193:311-4.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
30. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50(3):163-70.
31. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.
32. Tabar L, Fagerberg G, Chen HH, Duffy SW, Gad A. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-9.
33. McPherson CP, Swenson KK, Jolitz G, Murray CL. Breast carcinoma survival by detection method. Cancer 1997;79:1923-32.
34. Hellman S. Darwin's clinical relevance. Cancer 1997;79:2275-81.
35. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
36. Gasparini G, Weidner N, Bevilacqua P, Maluta S, Dalla Palma P, Caffo O, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-66.
37. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley P, Israel A, Liotta LA, editors. The molecular basis of cancer. Philadelphia: W.B. Saunders Company, 1995:206-24.
38. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996;88:1764-9.
39. Heimann R, Ferguson D, Powers C, Hellman S. Angiogenesis and estrogen receptor in young women with breast cancer [abstract]. Int J Radiat Oncol Biol Phys 1997;39(2S):136.
40. Lindfors KK, Rosenquist J. The cost-effectiveness of mammographic screening strategies. JAMA 1995;274:881-4.
41. Vogel VG. Screening younger women at risk for breast cancer. Monogr Natl Cancer Inst 1994;16:55-60.
42. Pauker SG, Kassirer JP. Contentious screening decisions: does the choice matter? N Engl J Med 1997;336:1243-4.